Treasury and IRS Promise 280E Relief Is Coming — Here’s What Cannabis Operators Actually Need to Know

For a decade, Section 280E has functioned as a slow bleed on the cannabis industry. The 1982 tax provision — written to punish drug dealers, not licensed businesses — has prevented state-legal cannabis operators from deducting ordinary business expenses from their federal taxes. Dispensaries and cultivators have paid effective tax rates sometimes exceeding 70 percent while competing businesses in other sectors deducted rent, payroll, and inventory costs as a matter of course.

That could be changing. On April 24 — one day after the Department of Justice issued its order moving state-licensed medical cannabis products from Schedule I to Schedule III under the Controlled Substances Act — the Treasury Department and Internal Revenue Service published a joint press release announcing that formal 280E guidance is forthcoming.

“Treasury and the IRS expect DOJ’s action to have significant positive tax consequences for businesses in the medical marijuana industry,” the agencies stated. “Treasury and the IRS plan to issue guidance to address the principal federal tax issues stemming from the Final Order.”

The statement doesn’t carry the force of law yet, but for operators who have spent years watching federal courts uphold 280E’s application to their businesses, it’s the most direct acknowledgment from federal tax authorities that the rescheduling changes everything.

What the Guidance Is Expected to Cover

The Treasury release outlined three main areas where guidance is anticipated:

280E applicability after rescheduling. The core question: does moving cannabis to Schedule III automatically free businesses from 280E’s restrictions? The agencies indicated the answer is broadly yes — “rescheduling generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances.” The word “generally” is doing significant work there, and the guidance is expected to clarify the specifics.

Multi-activity businesses. For operators who have both medical and non-medical lines — or who operate in states where some products qualify under the rescheduling order and others don’t — the guidance will address how 280E applies on a partial basis. The release signals that “section 280E applies only to those activities related to trafficking in Schedule I or II controlled substances,” meaning businesses may need to operationally separate qualifying and non-qualifying activities to maximize deduction eligibility.

Transition rules. Perhaps most practically, Treasury said guidance will include a transition rule establishing when rescheduling is considered to take effect for tax purposes. The language suggests the effective date will be treated as the beginning of the full taxable year that includes the Final Order’s effective date — not the order date itself, which was April 23, 2026. That distinction matters for how operators calculate deductions in their 2026 filings.

The DEA’s Parallel Moves

The IRS announcement landed alongside a busy stretch at the DEA, which has been implementing its end of the rescheduling order in parallel.

On April 28, the agency published notices in the Federal Register covering three areas: applications for businesses to handle medical marijuana as a Schedule III substance, an upcoming administrative hearing on whether non-medical marijuana should remain in Schedule I, and a notice formally withdrawing its original 2024 rescheduling proposal — replaced by the DOJ’s April 23 Final Order.

A new DEA registration portal went live April 29, allowing state-licensed medical dispensaries to apply for federal registration using their existing state credentials. The hearing on non-medical marijuana’s Schedule I status is set for June 29 through July 15. Interested parties have until May 28 to file participation requests.

That hearing matters. The DOJ’s order explicitly applies only to state-licensed medical cannabis products. Recreational-use products remain Schedule I, meaning adult-use dispensaries in states like Colorado, California, and Michigan may continue operating under 280E’s full constraints for the foreseeable future — or at minimum, until the June hearing produces some clarity.

Why Operators Shouldn’t Celebrate Too Fast

The Treasury statement is a signal, not a guarantee. Guidance has not yet been issued. The timeline is unspecified. And the fundamental ambiguity in the rescheduling structure — what exactly qualifies as “state-licensed medical marijuana” and which businesses fall under that umbrella — hasn’t been resolved in the public-facing documents.

Industry attorneys and accountants have been cautioning clients not to alter their tax treatment until the formal guidance arrives. The IRS tends to enforce existing rules until new guidance explicitly supersedes them, and operators who act on the assumption of 280E relief before that guidance drops could find themselves in a difficult position with auditors.

There’s also the open question of retroactivity. Operators have been overpaying federal taxes — in some estimates by hundreds of millions of dollars across the industry annually — for years. The Treasury statement focuses on future guidance, not past overpayments. Whether rescheduling creates a pathway for operators to seek refunds or amended returns for prior tax years is not addressed, and may not be included in the initial guidance at all.

What This Moment Actually Represents

Even with those caveats, the joint Treasury-IRS statement is significant for what it signals: the federal government is treating the rescheduling order as legally operative and is already working through its tax implications. That’s different from the limbo the industry has been in since rescheduling proceedings began in 2022.

Section 280E has been the single largest structural cost disadvantage facing the legal cannabis industry relative to the illicit market and other legitimate businesses. Eliminating it — or substantially limiting its application — would be the most concrete financial impact of rescheduling for most operators, outweighing changes to FDA oversight or banking access in the near term.

Treasury says guidance is coming. The industry is watching.

Ethan Vale covers cannabis policy and federal regulation for CannabisInquirer.com. Tips and documents: editorial@cannabisinquirer.com